Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey

Author:

,Cortinovis Diego1,Beretta Giordano2,Piazza Elena3,Luchena Giovanna4,Aglione Stefania5,Bertolini Alessandro6,Buzzoni Roberto7,Cabiddu Mary8,Carnaghi Carlo9,Danova Marco10,Farina Gabriella11,Ferrari Vittorio12,Frascaroli Mara13,Reni Michele14,Tansini Giuseppe15

Affiliation:

1. Oncologia Medica, San Gerardo Hospital, Monza

2. Oncologia Medica, Humanitas Gavazzeni, Bergamo

3. Oncologia Medica, L Sacco Hospital, Milan

4. Oncologia Medica, S Anna Hospital, Como:

5. Oncologia Medica, Vimercate Hospital, Monza

6. Oncologia Medica, Ospedale Civile, Sondrio

7. DH & Terapia Ambulatoriale Oncologica, Fondazione IRCCS Istituto Nazionale Tumori, Milan

8. Oncologia Medica, Ospedale Treviglio-Caravaggio, Bergamo

9. Oncologia Medica, Humanitas Mater Domini, Castellanza (VA), Onco-Ematologia, Humanitas Cancer Center, Rozzano (MI)

10. Medicina oncologica, Ospedale Civile, Vigevano (PV)

11. Oncologia Medica, Fatebenefratelli Hospital, Milan

12. Oncologia Medica, Spedali Civili, Brescia

13. Oncologia Medica, Fondazione Maugeri, Pavia

14. Oncologia Medica, San Raffaele Hospital, Milan

15. Oncologia Medica, Lodi Hospital, Lodi (MI), Italy

Abstract

Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior. Methods To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members. Results From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases. Conclusions Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3